Overview

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects

Status:
Terminated
Trial end date:
2020-12-11
Target enrollment:
Participant gender:
Summary
This is a phase 2, open-label, single-group, multicentre trial in which the investigational product, MC2-01 cream, is investigated in adolescent subjects (age 12 to 16 years, 11 months) with clinically diagnosed extensive psoriasis vulgaris.
Phase:
Phase 2
Details
Lead Sponsor:
Drug Delivery Solutions Ltd. (part of MC2 Therapeutics)
MC2 Therapeutics
Treatments:
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate